Hygromycin A Moving to Human Trials

January 4, 2024

A NEW TREATMENT FOR LYME DISEASE

The path to discovery

In 2015, GLA funded a drug discovery program with Dr. Kim Lewis at Northeastern University, leading to the discovery of hygromycin A, an overlooked antibiotic from 1953. Fast forward to 2021, and Dr. Lewis’s lab revealed that hygromycin A is highly effective against Lyme bacteria and can potentially cure early Lyme disease and prevent chronic conditions.

Building upon this discovery, GLA proudly partnered with Dr. Lewis and Flightpath Biosciences, a biotechnology company. GLA Chief Scientific Officer Timothy Sellati, Ph.D., says, “Flightpath Biosciences will usher hygromycin A along the commercialization path, through clinical trials and FDA approval, ultimately reaching physicians.” Remarkably, not only does hygromycin A kill the Lyme bacteria in the test tube and in animal studies but unlike antibiotics such as doxycycline, it is unlikely to harm the ‘good’ bacteria in a patient’s intestines.

Today, GLA is excited to announce that hygromycin A (FP-100) is moving into the clinic in Q1 2024 for human clinical trials. CEO of Flightpath Biosciences, Matt Tindall, emphasizes, “This landmark achievement for Lyme patients could not have been reached without the kind and generous financial support of GLA and its community.” 

We eagerly anticipate progress and the road ahead, working together to bring hygromycin A (FP-100) into the hands of physicians.

_________________

**Comment**

While not diminishing the potential importance of this, it’s use in preventing or treating persistent infections was not determined.  The subset of patients with chronic debilitating symptoms continues to be ignored.  

For more:

Category:

Lyme, research, Treatment

Comments Off on Hygromycin A Moving to Human Trials